Home | Nephrology Conference | Longdom Conference

Why Racial and Ethnic Disparities Exist in Kidney Disease Care

2021-04-05 - 2021-04

Racial and ethnic disparities permeate much of the healthcare system in the United States. Numerous studies have documented that Black individuals ...

Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease

2021-07-14 - 2021-07

The Food and Drug Administration (FDA) has approved Kerendia® (finerenone) to reduce the risk of sustained estimated glomerular filtration (eGFR) decline, end stage kidney disease, cardiovascular death, nonfatal myocardial infarction (MI) and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Kerendia is a nonsteroidal selective mineralocorticoid receptor (MR) antagonist that works by blocking MR mediated sodium reabsorption and MR overactivation in both epithelial (eg, kidney) and nonepithelial (eg, heart and blood vessels) tissues. Mineralocorticoid receptor overactivation is believed to contribute to fibrosis and inflammation.

CKD Hospitalization Patterns May Predict ESKD, Death Risks

2021-07-06 - 2021-07

Patients with chronic kidney disease (CKD) who are more frequently hospitalized are more likely progress to end-stage kidney disease (ESKD) or die compared with patients who are rarely hospitalized, independent of traditional risk factors, a new study finds. Among 3012 individuals with CKD stages 2 to 4 in the Chronic Renal Insufficiency Cohort (CRIC) study, 5658 hospitalizations occurred within 4 years. The high-, intermediate-, and low-utilizer groups had a mean 6.3, 2.2, and 0 all-cause hospitalizations, respectively, over the period, Anand Srivastava, MD, MPH, of Northwestern University Feinberg School of Medicine in Chicago, Illinois, and colleagues reported in Kidney International Reports. For both high and intermediate utilizers, the top 5 reasons for hospitalization were circulatory system disorders, infectious diseases, endocrine disorders, musculoskeletal system disorders, and injury and poisoning. High utilizers had a significantly longer hospital stay compared with intermediate and low utilizers: 1.6 vs 0.5 vs 0 days, respectively, according to the investigators. Patients in the high-utilizer group also were significantly more likely to be rehospitalized within 30 days: 31.4% vs 12.9% vs 0%, respectively. After the 4 year period, 544 ESKD events and 437 ESKD-censored deaths occurred during a median follow-up duration of 5.1 years. In adjusted analyses, intermediate and high utilizers had a 1.5- and 1.8-fold higher risk of ESKD, respectively, compared with low utilizers, Dr Srivastava’s team reported. Intermediate and high utilizers also had a 1.5- and 2.6-fold higher risk of ESKD-censored death, respectively.

CKD Hospitalization Patterns May Predict ESKD, Death Risks

2021-07-06 - 2021-07

Nephrology

Briefly Know About This Event

Awards

@

Scientific

Program

Sessions

& Tracks

Conference

Blog

Scientific Tracks

Our Brilliant Speakers

Hany Helmy Saad Attia

Baris Cankaya

Media Partners

What Client's Say

Dr. Simona Caporali

Dr. Anita Sahu-Osen

Dr. Duygu Selcuklu

Dr. Aoife Kiely

Abstracts enquiry

Registration enquiry

Contact Enquiry

Phone

WhatsApp

Useful Links

News

Why Racial and Ethnic Disparities Exist in Kidney Disease Care

Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease

CKD Hospitalization Patterns May Predict ESKD, Death Risks

CKD Hospitalization Patterns May Predict ESKD, Death Risks

Newsletter